skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: DOAJ Directory of Open Access Journals remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma
45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma

Choueiri, Toni K ; Powles, Thomas ; Braun, David ; Fong, Lawrence ; George, Daniel ; Haas, Naomi ; McDermott, David F ; Shuch, Brian ; Gurney, Howard ; Meehan, Robert ; Posadas, Tracey ; Wu, Sterling ; Elfiky, Aymen ; Motzer, Robert J

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S15-S15 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
2
19 Phase II Trial of Ubamatamab in MUC16-Expressing SMARCB1-Deficient Renal Medullary Carcinoma and Epithelioid Sarcoma
19 Phase II Trial of Ubamatamab in MUC16-Expressing SMARCB1-Deficient Renal Medullary Carcinoma and Epithelioid Sarcoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

19 Phase II Trial of Ubamatamab in MUC16-Expressing SMARCB1-Deficient Renal Medullary Carcinoma and Epithelioid Sarcoma

Msaouel, Pavlos

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S13-S14 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
3
5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605
5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605
Material Type:
Artigo 		Adicionar ao Meu Espaço

5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605

McKay, Rana R ; Garmezy, Ben ; Barata, Pedro ; Ornstein, Moshe ; Shah, Neil J ; Hammers, Hans ; Hutson, Thomas E ; Chisamore, Michael ; Karim, Dhamina ; Mattson, Paulette ; Lightcap, Eric ; Drees, Jeremy ; Harrison, Ben ; Holm, Megan ; Bose, Nandita ; Thomas, Cherry T ; Motzer, Robert J

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S13-S13 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
4
Advanced Renal Cell Cancer Combination Immunotherapy Clinical Trial (ARCITECT; HCRN GU 22-587)
Advanced Renal Cell Cancer Combination Immunotherapy Clinical Trial (ARCITECT; HCRN GU 22-587)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Advanced Renal Cell Cancer Combination Immunotherapy Clinical Trial (ARCITECT; HCRN GU 22-587)

Serzan, Michael

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S12-S13 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
5
75 WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer
75 WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

75 WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer

Stewart, Professor Grant ; Jones, James ; Warren, Anne ; Gallagher, Professor Ferdia ; Menih, Ines Horvat ; Mossop, Helen ; Wason, Professor James ; Easita, Farhana ; Thomas, Martin ; Welsh, Sarah ; Mitchell, Mr Tom ; Ursprung, Stephan ; O’Carrigan, Brent

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S15-S16 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
6
29 Pilot study of an implantable microdevice forin vivo evaluation of drug response in renal cell carcinoma (NCT05700461)
29 Pilot study of an implantable microdevice forin vivo evaluation of drug response in renal cell carcinoma (NCT05700461)
Material Type:
Artigo 		Adicionar ao Meu Espaço

29 Pilot study of an implantable microdevice forin vivo evaluation of drug response in renal cell carcinoma (NCT05700461)

Xu, Wenxin ; Bhagavatula, Sharath ; Steiner, Clara ; Zhong, Caiwei ; Mossanen, Matthew ; Chang, Steven ; Hirsch, Michelle ; Ahn, Sebastian ; Matthew, Destiny ; Berg, Stephanie ; Serzan, Michael ; McGregor, Bradley ; Hata, Nobuhiko ; Viswanathan, Srinivas ; Silverman, Stuart ; Jonas, Oliver ; Choueiri, Toni

The oncologist (Dayton, Ohio), 2024-08, Vol.29 (Suppl 1), p.S14-S15 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
7
Abstract 1601 Use of Interactive Progress Curves in an OER to Teach Kinetics in Biochemistry
Abstract 1601 Use of Interactive Progress Curves in an OER to Teach Kinetics in Biochemistry
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract 1601 Use of Interactive Progress Curves in an OER to Teach Kinetics in Biochemistry

Jakubowski, Henry ; Agnew, Henry ; Jardine, Bartholomew ; Sauro, Herbert

The Journal of biological chemistry, 2024-03, Vol.300 (3), p.105924, Article 105924 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
8
LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma
LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma

McDermott, David F ; Peer, Avivit ; Agarwal, Neeraj ; Atkins, Michael B ; Cornell, Jerry ; Perini, Rodolfo F ; Grossmann, Kenneth F ; Gurney, Howard

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S11-S11 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
9
A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC
A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC

Jonasch, Eric ; Hauke, Ralph ; Falchook, Gerald ; Logan, Theodore ; Gordon, Michael ; Hall, Evan ; Schuch, Brian ; Bilen, Mehmet A ; Naqash, Abdul ; Zakaharia, Yousef ; Ryan, Christopher W ; Lally, Satwant ; Xiao, Jim ; Zimmerman, Zachary ; Srinivasan, Ramaprasad ; Choueiri, Toni K

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S12-S12 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
10
Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma
Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma

Beckermann, Kathryn ; Rini, Brian ; Haas, Naomi ; George, Daniel ; Jonasch, Eric

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S13-S14 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (4.887)
  2. Revistas revisadas por pares (4.980)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (5.460)
  2. Resenhas  (27)
  3. Anais de Congresso  (17)
  4. magazinearticle  (16)
  5. Web Resources  (2)
  6. Reports  (1)
  7. Conjunto de Dados  (1)
  8. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1963  (40)
  2. 1963Até1977  (53)
  3. 1978Até1992  (115)
  4. 1993Até2008  (489)
  5. Após 2008  (4.826)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (4.524)
  2. Espanhol  (389)
  3. Chinês  (357)
  4. Português  (299)
  5. Alemão  (160)
  6. Japonês  (139)
  7. Russo  (88)
  8. Francês  (83)
  9. Persa  (73)
  10. Croatian  (63)
  11. Polonês  (23)
  12. Árabe  (22)
  13. Italiano  (20)
  14. Serbian  (16)
  15. Tcheco  (14)
  16. Romeno  (13)
  17. Norueguês  (11)
  18. Africâner  (11)
  19. Esloveno  (10)
  20. Catalão  (9)
  21. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.